Volume 20, Number 3—March 2014
Cutaneous Leishmaniasis Caused by Leishmania killicki, Algeria
Highlight and copy the desired format.
|EID||Izri A, Bendjaballah A, Andriantsoanirina V, Durand R. Cutaneous Leishmaniasis Caused by Leishmania killicki, Algeria. Emerg Infect Dis. 2014;20(3):502-504. https://dx.doi.org/10.3201/eid2003.131152|
|AMA||Izri A, Bendjaballah A, Andriantsoanirina V, et al. Cutaneous Leishmaniasis Caused by Leishmania killicki, Algeria. Emerging Infectious Diseases. 2014;20(3):502-504. doi:10.3201/eid2003.131152.|
|APA||Izri, A., Bendjaballah, A., Andriantsoanirina, V., & Durand, R. (2014). Cutaneous Leishmaniasis Caused by Leishmania killicki, Algeria. Emerging Infectious Diseases, 20(3), 502-504. https://dx.doi.org/10.3201/eid2003.131152.|
To the Editor: Cutaneous leishmaniasis (CL) is a widespread and resurging vector-borne disease caused by a protozoan parasite belonging to genus Leishmania (1). After Afghanistan, Algeria is the second largest focus of CL in the world. Although CL is a serious public health problem in Algeria, few data are available from this country.
During 2004–2008, an average of ≈44,050 CL cases were reported per year, and the estimated annual incidence ranged from 123,300 to 202,600 cases. Two main forms of CL have been described for more than a century in Algeria, the zoonotic, caused by L. major and the sporadic, caused by L. infantum. Since 2004, 11 strains belonging to the L. tropica complex, including L. killicki (2), were identified in 1 focus in the northern part of the Sahara (3) and in 2 foci in the northeastern Algeria (4,5). We report here a recent outbreak of CL, including infection with L. killicki strains, in the Tipaza area of northern Algeria.
Patients who sought treatment at Hajout hospital in Hajout, Algeria (a community of ≈51,000 persons), from January 2010 through April 2013 with cutaneous lesions consistent with leishmaniasis, underwent clinical examination. For each patient (146 total), we collected epidemiologic data (geographic origin, traveling history, especially to other leishmaniasis-endemic areas) and clinical data (number and size of lesions and clinical forms). Informed consent was obtained from all patients or their legal guardians. A particular characteristic of the infections was the unusual duration of some episodes, one of which persisted for >4 years, which is compatible with leishmania recidivans (6).
Microbiological data were obtained as follows. Tissue samples, obtained by scraping the internal border of skin lesions from patients, were smeared onto a glass slide, fixed with methanol, stained with Giemsa, and examined by microscopy. Slides showing Leishmania amastigote forms were then processed further for molecular analyses. The immersion oil used to examine each slide was wiped off the smear with tissue paper, and then the dry smear was scraped from its slide by using a sterile scalpel. DNA extraction from smear scrapings was performed with the NucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany). Species identification was performed by amplifying the topoisomerase II gene, followed by DNA sequencing (7).
In total, 60 patients exhibited Leishmania-positive cutaneous lesions as determined by microscopy. The topoisomerase II gene was successfully amplified and sequenced from samples from 38 patients. Leishmania species were identified by comparing sequences with those of the reference strains L. infantum MHOM/FR/78/LEM75, L. killicki MHOM/TN/80/LEM163, and L. major MHOM/MA/81/LEM265 (7). L. infantum was identified in 36 cases and L. killicki in 2 cases (Figure). No L. major isolates were found in this series.
The low proportion of L. killicki strains was similar to that found recently in the Annaba focus in northeastern Algeria (5). However, the observation of a new focus of CL and L. killicki as etiologic agent may indicate a modification of the epidemiology of CL in Algeria. This focus, located far from other previously described areas where the L. tropica complex is endemic, may reflect geographic spread of this complex in Algeria.
The results of this study can be placed in a larger framework as well. Since 2004, strains in the L. tropica complex have been increasingly reported as responsible for CL in Mediterranean countries, in the Near East and Middle-East (2), possibly in relation to changes in environmental conditions. Urbanization and/or climatic changes that have occurred in recent years could have played a role in the spread of the disease. The cases reported here were observed in urban areas, which suggests transmission according to an anthroponotic mode.
Each species responsible for CL has its own epidemiologic pattern. Clinicians must be aware of the specificity of leishmaniases that may be encountered in North African countries. L. tropica complex lesions heal spontaneously over a period of 12 months or more, a duration longer than for L. major infections (8). L. tropica infections are also less responsive to treatment compared to infections with other Old World Leishmania species. In addition, L. tropica may cause leishmania recidivans. This type of CL, appearing often years after the initial infection showed signs of complete resolution, manifests as papules that transform slowly into a spreading granuloma resembling lupus vulgaris (6). L. tropica can also produce visceral infections on rare occasions, resulting in unexplained systemic illness, including classic symptoms of visceral leishmaniasis, in persons returning from areas where this Leishmania complex is endemic (9).
Other epidemiologic studies are required to detect additional foci, including those of the L. tropica complex, that may coexist with those of L. infantum and L. major in Algeria. Travelers to North Africa should also be informed about the existence of this spreading disease (10).
- Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671 .
- Pratlong F, Dereure J, Ravel C, Lami P, Balard Y, Serres G, Geographical distribution and epidemiological features of Old World cutaneous leishmaniasis foci, based on the isoenzyme analysis of 1048 strains. Trop Med Int Health. 2009;14:1071–85 .
- Harrat Z, Boubidi SC, Pratlong F, Benikhlef R, Selt B, Dedet JP, Description of a dermatropic Leishmania close to L. killicki (Rioux, Lanotte & Pratlong 1986) in Algeria. Trans R Soc Trop Med Hyg. 2009;103:716–20 .
- Mihoubi I, Picot S, Hafirassou N, de Monbrison F. Cutaneous leishmaniasis caused by Leishmania tropica in Algeria. Trans R Soc Trop Med Hyg. 2008;102:1157–9.
- Mansouri R, Pratlong F, Bachi F, Hamrioui B, Dedet JP. The first isoenzymatic characterizations of the Leishmania strains responsible for cutaneous leishmaniasis in the area of Annaba (Eastern Algeria) [cited 2014 Jan 16]. The Open Conference Proceedings Journal. 2012;3 (Suppl.2–M2):6–11. http://www.benthamsciencepublisher.com/open/toprocj/articles/V003/SS0001TOPROCJ/6TOPROCJ.pdf
- Klaus S, Frankenburg S. Cutaneous leishmaniasis in the Middle East. Clin Dermatol. 1999;17:137–41.
- Haouas N, Garrab S, Gorcii M, Khorchani H, Chargui N, Ravel C, Development of a polymerase chain reaction-restriction fragment length polymorphism assay for Leishmania major/Leishmania killicki/ Leishmania infantum discrimination from clinical samples, application in a Tunisian focus. Diagn Microbiol Infect Dis. 2010;68:152–8.
- Morizot G, Kendjo E, Mouri O, Thellier M, Pérignon A, Foulet F, Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis. 2013;57:370–80.
- Magill AJ, Grogl M, Gasser RA, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med. 1993;328:1383–7.
- Maubon D, Thurot-Guillou C, Ravel C, Leccia MT, Pelloux H. Leishmania killicki imported from Tunisian desert. Emerg Infect Dis. 2009;15:1864–5.
- Figure. . Alignment of topoisomerase II nucleotide sequences of Leishmania killicki, L. infantum, and L. major. Point mutations discriminating Leishmania species are outlined on a gray background. The references strains are...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Rémy Durand, Service de Parasitologie-Mycologie, Hôpital Avicenne, 125 rue de Stalingrad 93009 Bobigny Cedex, FranceRémy Durand, Service de Parasitologie-Mycologie, Hôpital Avicenne, 125 rue de Stalingrad 93009 Bobigny Cedex, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: February 20, 2014
- Page last updated: February 20, 2014
- Page last reviewed: February 20, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)